Lixte Biotechnology Holdings, Inc.
LIXT
Price:
$1.87
Market Cap:
$4.21M
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and L...[Read more]
Industry
Biotechnology
IPO Date
2007-10-25
Stock Exchange
NASDAQ
Ticker
LIXT
PE Ratio
[-1.09]
ROE
[-112.90%]
Current Ratio
[6.33]
Dividend Yield
[0%]
Enterprise Value
[1.61M]
Dividend History
The ROE as of November 2024 (TTM) for Lixte Biotechnology Holdings, Inc. (LIXT) is -112.90%
According to Lixte Biotechnology Holdings, Inc.’s latest financial reports and current stock price. The company's current ROE is -112.90%. This represents a change of 268.31% compared to the average of -30.65% of the last 4 quarters.
Lixte Biotechnology Holdings, Inc. (LIXT) Historical ROE (quarterly & annually)
How has LIXT ROE performed in the past?
The mean historical ROE of Lixte Biotechnology Holdings, Inc. over the last ten years is -373.44%. The current -112.90% ROE has changed -69.77% with respect to the historical average. Over the past ten years (40 quarters), LIXT's ROE was at its highest in in the September 2018 quarter at 7.33%. The ROE was at its lowest in in the December 2016 quarter at -240.39%.
Average
-373.44%
Median
-133.97%
Minimum
-1040.46%
Maximum
-51.70%
Lixte Biotechnology Holdings, Inc. (LIXT) ROE by Quarter and Year
Discovering the peaks and valleys of Lixte Biotechnology Holdings, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 115.94%
Maximum Annual ROE = -51.70%
Minimum Annual Increase = -81.72%
Minimum Annual ROE = -1040.46%
| Year | ROE | Change |
|---|---|---|
| 2023 | -127.34% | 4.33% |
| 2022 | -122.06% | -13.19% |
| 2021 | -140.60% | 115.94% |
| 2020 | -65.11% | -33.70% |
| 2019 | -98.21% | 89.96% |
| 2018 | -51.70% | -71.55% |
| 2017 | -181.74% | -81.72% |
| 2016 | -994.01% | 8.85% |
| 2015 | -913.16% | -12.23% |
| 2014 | -1040.46% | 78.80% |
Lixte Biotechnology Holdings, Inc. (LIXT) Average ROE
How has LIXT ROE performed in the past?
The current ROE of Lixte Biotechnology Holdings, Inc. (LIXT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-130.00%
5-year avg
-110.67%
10-year avg
-373.44%
Lixte Biotechnology Holdings, Inc. (LIXT) ROE vs. Peers
How is LIXT’s ROE compared to its peers?
Lixte Biotechnology Holdings, Inc.’s ROE is greater than Allarity Therapeutics, Inc. (-704.78%), greater than NeuroBo Pharmaceuticals, Inc. (-154.04%), greater than Hillstream BioPharma, Inc. (-47249.59%), greater than Virax Biolabs Group Limited (-115.10%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than Indaptus Therapeutics, Inc. (-146.70%), greater than Pasithea Therapeutics Corp. (-74.63%), less than Kiromic BioPharma, Inc. (337.72%), greater than Biodexa Pharmaceuticals Plc (-101.74%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Olema Pharmaceuticals, Inc. (-44.18%), greater than Enochian Biosciences, Inc. (-47.54%), greater than Scholar Rock Holding Corporation (-114.96%), greater than Passage Bio, Inc. (-70.73%),
| Company | ROE | Market cap |
|---|---|---|
| -704.78% | $1.98M | |
| -154.04% | $21.22M | |
| -47249.59% | $4.17M | |
| -115.10% | $8.81M | |
| -112.11% | $2.85M | |
| -146.70% | $12.03M | |
| -74.63% | $3.93M | |
| 337.72% | $1.73M | |
| -101.74% | $3.30M | |
| -21.96% | $84.75M | |
| -44.18% | $680.32M | |
| -47.54% | $45.38M | |
| -114.96% | $2.50B | |
| -70.73% | $37.36M |
Build a custom stock screener for Lixte Biotechnology Holdings, Inc. (LIXT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lixte Biotechnology Holdings, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Lixte Biotechnology Holdings, Inc. (LIXT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Lixte Biotechnology Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Lixte Biotechnology Holdings, Inc.'s ROE?
How is the ROE calculated for Lixte Biotechnology Holdings, Inc. (LIXT)?
What is the highest ROE for Lixte Biotechnology Holdings, Inc. (LIXT)?
What is the 3-year average ROE for Lixte Biotechnology Holdings, Inc. (LIXT)?
What is the 5-year average ROE for Lixte Biotechnology Holdings, Inc. (LIXT)?
How does the current ROE for Lixte Biotechnology Holdings, Inc. (LIXT) compare to its historical average?